Related Experiment Video
Updated: Jun 11, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer
Yosuke Harada1, Mitsugu Kanehira, Yoshiko Fujisawa
1Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Abstract:
Bladder cancer is the second most common genitourinary cancer worldwide, yet its oncogenic origins remain poorly understood. The cancer-testis antigen DEPDC1 was shown recently to contribute to bladder cancer oncogenesis. In this study, we examined the biological functions of DEPDC1 and defined a potential therapeutic strategy to target this molecule. Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. Inhibiting this interaction with a cell-permeable peptide corresponding to the ZNF224-interacting domain in DEPDC1 induced apoptosis of bladder cancer cells in vitro and in vivo. By inhibiting DEPDC1-ZNF224 complex formation, this peptide triggered transcriptional activation of A20, a potent inhibitor of the NF-kappaB signaling pathway. Our findings indicate that the DEPDC1-ZNF224 complex is likely to play a critical role in bladder carcinogenesis.
Insights
Researchers identified a critical interaction between DEPDC1 and ZNF224 in bladder cancer. Inhibiting this complex with a peptide therapy induced cancer cell death by activating A20 and suppressing NF-kappaB signaling.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Bladder cancer is a prevalent genitourinary malignancy with incompletely understood oncogenic drivers.
- The cancer-testis antigen DEP domain-containing protein 1 (DEPDC1) has emerged as a potential contributor to bladder cancer development.
Purpose of the Study:
- To elucidate the biological functions of DEPDC1 in bladder cancer.
- To define a novel therapeutic strategy targeting DEPDC1.
Main Methods:
- Coimmunoprecipitation and immunocytochemistry were employed to investigate protein interactions.
- Cell-permeable peptides were designed to inhibit specific protein-protein interactions.
- In vitro and in vivo assays were conducted to assess therapeutic efficacy.
Main Results:
- DEPDC1 was found to interact and colocalize with the transcriptional repressor zinc finger protein 224 (ZNF224).
- A cell-permeable peptide targeting the DEPDC1-ZNF224 interaction induced apoptosis in bladder cancer cells.
- This inhibition led to the transcriptional activation of A20, a negative regulator of the NF-kappaB pathway.
Conclusions:
- The DEPDC1-ZNF224 complex plays a significant role in bladder cancer progression.
- Targeting this complex represents a promising therapeutic avenue for bladder cancer treatment.
Related Concept Videos
Abnormal Proliferation
Canonical Wnt Signaling Pathway
Induced Pluripotent Stem Cells
Somatic cells are...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
